Cargando…

Glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient iPSC models of frontotemporal dementia

ABSTRACT: Frontotemporal dementia (FTD) is amongst the most prevalent early onset dementias and even though it is clinically, pathologically and genetically heterogeneous, a crucial involvement of metabolic perturbations in FTD pathology is being recognized. However, changes in metabolism at the cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Aldana, Blanca I., Zhang, Yu, Jensen, Pia, Chandrasekaran, Abinaya, Christensen, Sofie K., Nielsen, Troels T., Nielsen, Jørgen E., Hyttel, Poul, Larsen, Martin R., Waagepetersen, Helle S., Freude, Kristine K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491073/
https://www.ncbi.nlm.nih.gov/pubmed/32928252
http://dx.doi.org/10.1186/s13041-020-00658-6
_version_ 1783582146097577984
author Aldana, Blanca I.
Zhang, Yu
Jensen, Pia
Chandrasekaran, Abinaya
Christensen, Sofie K.
Nielsen, Troels T.
Nielsen, Jørgen E.
Hyttel, Poul
Larsen, Martin R.
Waagepetersen, Helle S.
Freude, Kristine K.
author_facet Aldana, Blanca I.
Zhang, Yu
Jensen, Pia
Chandrasekaran, Abinaya
Christensen, Sofie K.
Nielsen, Troels T.
Nielsen, Jørgen E.
Hyttel, Poul
Larsen, Martin R.
Waagepetersen, Helle S.
Freude, Kristine K.
author_sort Aldana, Blanca I.
collection PubMed
description ABSTRACT: Frontotemporal dementia (FTD) is amongst the most prevalent early onset dementias and even though it is clinically, pathologically and genetically heterogeneous, a crucial involvement of metabolic perturbations in FTD pathology is being recognized. However, changes in metabolism at the cellular level, implicated in FTD and in neurodegeneration in general, are still poorly understood. Here we generate induced human pluripotent stem cells (hiPSCs) from patients carrying mutations in CHMP2B (FTD3) and isogenic controls generated via CRISPR/Cas9 gene editing with subsequent neuronal and glial differentiation and characterization. FTD3 neurons show a dysregulation of glutamate-glutamine related metabolic pathways mapped by (13)C-labelling coupled to mass spectrometry. FTD3 astrocytes show increased uptake of glutamate whilst glutamate metabolism is largely maintained. Using quantitative proteomics and live-cell metabolic analyses, we elucidate molecular determinants and functional alterations of neuronal and glial energy metabolism in FTD3. Importantly, correction of the mutations rescues such pathological phenotypes. Notably, these findings implicate dysregulation of key enzymes crucial for glutamate-glutamine homeostasis in FTD3 pathogenesis which may underlie vulnerability to neurodegeneration. GRAPHICAL ABSTRACT: Neurons derived from human induced pluripotent stem cells (hiPSCs) of patients carrying mutations in CHMP2B (FTD3) display major metabolic alterations compared to CRISPR/Cas9 generated isogenic controls. Using quantitative proteomics, (13)C-labelling coupled to mass spectrometry metabolic mapping and seahorse analyses, molecular determinants and functional alterations of neuronal and astrocytic energy metabolism in FTD3 were characterized. Our findings implicate dysregulation of glutamate-glutamine homeostasis in FTD3 pathogenesis. In addition, FTD3 neurons recapitulate glucose hypometabolism observed in FTD patient brains. The impaired mitochondria function found here is concordant with disturbed TCA cycle activity and decreased glycolysis in FTD3 neurons. FTD3 neuronal glutamine hypermetabolism is associated with up-regulation of PAG expression and, possibly, ROS production. Distinct compartments of glutamate metabolism can be suggested for the FTD3 neurons. Endogenous glutamate generated from glutamine via PAG may enter the TCA cycle via AAT (left side of neuron) while exogenous glutamate taken up from the extracellular space may be incorporated into the TCA cycle via GDH (right side of the neuron) FTD3 astrocytic glutamate uptake is upregulated whilst glutamate metabolism is largely maintained. Finally, pharmacological reversal of glutamate hypometabolism manifesting from decreased GDH expression should be explored as a novel therapeutic intervention for treating FTD3. [Image: see text]
format Online
Article
Text
id pubmed-7491073
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74910732020-09-16 Glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient iPSC models of frontotemporal dementia Aldana, Blanca I. Zhang, Yu Jensen, Pia Chandrasekaran, Abinaya Christensen, Sofie K. Nielsen, Troels T. Nielsen, Jørgen E. Hyttel, Poul Larsen, Martin R. Waagepetersen, Helle S. Freude, Kristine K. Mol Brain Research ABSTRACT: Frontotemporal dementia (FTD) is amongst the most prevalent early onset dementias and even though it is clinically, pathologically and genetically heterogeneous, a crucial involvement of metabolic perturbations in FTD pathology is being recognized. However, changes in metabolism at the cellular level, implicated in FTD and in neurodegeneration in general, are still poorly understood. Here we generate induced human pluripotent stem cells (hiPSCs) from patients carrying mutations in CHMP2B (FTD3) and isogenic controls generated via CRISPR/Cas9 gene editing with subsequent neuronal and glial differentiation and characterization. FTD3 neurons show a dysregulation of glutamate-glutamine related metabolic pathways mapped by (13)C-labelling coupled to mass spectrometry. FTD3 astrocytes show increased uptake of glutamate whilst glutamate metabolism is largely maintained. Using quantitative proteomics and live-cell metabolic analyses, we elucidate molecular determinants and functional alterations of neuronal and glial energy metabolism in FTD3. Importantly, correction of the mutations rescues such pathological phenotypes. Notably, these findings implicate dysregulation of key enzymes crucial for glutamate-glutamine homeostasis in FTD3 pathogenesis which may underlie vulnerability to neurodegeneration. GRAPHICAL ABSTRACT: Neurons derived from human induced pluripotent stem cells (hiPSCs) of patients carrying mutations in CHMP2B (FTD3) display major metabolic alterations compared to CRISPR/Cas9 generated isogenic controls. Using quantitative proteomics, (13)C-labelling coupled to mass spectrometry metabolic mapping and seahorse analyses, molecular determinants and functional alterations of neuronal and astrocytic energy metabolism in FTD3 were characterized. Our findings implicate dysregulation of glutamate-glutamine homeostasis in FTD3 pathogenesis. In addition, FTD3 neurons recapitulate glucose hypometabolism observed in FTD patient brains. The impaired mitochondria function found here is concordant with disturbed TCA cycle activity and decreased glycolysis in FTD3 neurons. FTD3 neuronal glutamine hypermetabolism is associated with up-regulation of PAG expression and, possibly, ROS production. Distinct compartments of glutamate metabolism can be suggested for the FTD3 neurons. Endogenous glutamate generated from glutamine via PAG may enter the TCA cycle via AAT (left side of neuron) while exogenous glutamate taken up from the extracellular space may be incorporated into the TCA cycle via GDH (right side of the neuron) FTD3 astrocytic glutamate uptake is upregulated whilst glutamate metabolism is largely maintained. Finally, pharmacological reversal of glutamate hypometabolism manifesting from decreased GDH expression should be explored as a novel therapeutic intervention for treating FTD3. [Image: see text] BioMed Central 2020-09-14 /pmc/articles/PMC7491073/ /pubmed/32928252 http://dx.doi.org/10.1186/s13041-020-00658-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Aldana, Blanca I.
Zhang, Yu
Jensen, Pia
Chandrasekaran, Abinaya
Christensen, Sofie K.
Nielsen, Troels T.
Nielsen, Jørgen E.
Hyttel, Poul
Larsen, Martin R.
Waagepetersen, Helle S.
Freude, Kristine K.
Glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient iPSC models of frontotemporal dementia
title Glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient iPSC models of frontotemporal dementia
title_full Glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient iPSC models of frontotemporal dementia
title_fullStr Glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient iPSC models of frontotemporal dementia
title_full_unstemmed Glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient iPSC models of frontotemporal dementia
title_short Glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient iPSC models of frontotemporal dementia
title_sort glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient ipsc models of frontotemporal dementia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491073/
https://www.ncbi.nlm.nih.gov/pubmed/32928252
http://dx.doi.org/10.1186/s13041-020-00658-6
work_keys_str_mv AT aldanablancai glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia
AT zhangyu glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia
AT jensenpia glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia
AT chandrasekaranabinaya glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia
AT christensensofiek glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia
AT nielsentroelst glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia
AT nielsenjørgene glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia
AT hyttelpoul glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia
AT larsenmartinr glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia
AT waagepetersenhelles glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia
AT freudekristinek glutamateglutaminehomeostasisisperturbedinneuronsandastrocytesderivedfrompatientipscmodelsoffrontotemporaldementia